Publications i-Target 1.0

92. Märkl F, Benmebarek MR, Keyl J, Cadilha BL, Geiger M, Karches C, Obeck H, Schwerdtfeger M, Michaelides S, Briukhovetska D, Stock S, Jobst J, Müller PJ, Majed L, Seifert M, Klüver AK, Lorenzini T, Grünmeier R, Thomas M, Gottschlich A, Klaus R, Marr C, von Bergwelt-Baildon M, Rothenfusser S, Levesque MP, Heppt MV, Endres S, Klein C, Kobold S.
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
Journal for Immunotherapy of Cancer 2023 ;11:e006436. doi;
JIF 12.5

91. Vornholz L, Isay SE, Kurgyis Z, Strobl DC, Loll P, Mosa MH, Luecken MD, Sterr M, Lickert H, Winter C, Greten FR, Farin HF, Theis FJ, Ruland J.
Synthetic enforcement of STING signaling in cancer cells appropriates the immune microenvironment for checkpoint inhibitor therapy.
Science Advances 2023; 9 eadd8564.de
JIF 14

90. Tao Xu T, Karschnia P, Cadilha B, Dede S, Lorenz M, Seewaldt N, Nikolaishvili E, Müller K, Blobner J, Teske J, Herold J, Rejeski K, Langer S, Obeck H, Lorenzini T, Mulazzani M, Zhang W, Ishikawa-Ankerhold H, Buchholz V, Subklewe M, Thon N, Straube A, Tonn JC, Kobold S, von Baumgarten L.
In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer.
OncoImmunology 2023; in press.

89. Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou A, Schuebel M, Jobst J, Zhang T, Doerr J, Märkl F, Majed L, Müller PJ, May P, Gottschlich A, Tokarew N, Leucke J, Oener A, Schwerdtfeger M, Andreu-Sanz D, Gruenmeier R, Seifert M, Michaelides S, Hristov M, Koenig LM, Cadilha B, Mikhaylov O, Anders HJ, Rothenfusser S, Flavell R, Cerezo-Wallis D, Tejedo C, Soengas M, Bald T, Huber S, Endres S, Kobold S.
T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.
Immunity 2023; 143-161.e11.
JIF 43.5

88. Karl F, Liang C, Boettcher-Loschinski R, Stoll A, Flamann CS, Richter S, Lischer C, Völkl S, Jacobs B, Böttcher M, Jitschin R, Bruns H, Fischer T, Holler E, Roesler W, Dandekar T, Mackensen A, Mougiakakos D.

Oxidative DNA damage in reconstituting T-cells is associated with relapse and inferior survival following Allo-SCT.
Blood 2022: 2022017267.
JIF: 25.5

87. Seifert M, Benmebarek MR, Briukhovetska D, Märkl F, Dörr J, Cadilha B, Jobst J, Stock S, Andreu-Sanz D, Lorenzini T, Grünmeier R, Öner A, Obeck H, Majed L, Dhoqina D, Feinendegen M, Gottschlich A, Zhang J, Schindler U, Endres S, Kobold S.
Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function.
British Journal of Cancer 2022; 61, eabe2550.
JIF 9.1

86. Stock S, Benmebarek MR, Kluever AK, Darowski D, Jost Ch, Stubenrauch KG, Benz J, Freimoser-Grundschober A, Moessner E, Umana P, Subklewe M, Endres S, Klein Ch, Kobold S.
Chimeric antigen receptor T cells engineered to recogniz the P329G- mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Journal for Immunotherapy of Cancer 2022; 10:e005054.
JIF 12.5

85. Dickopf S, Buldun C, Vasic V, Georges G, Hage C, Mayer K, Forster M, Wessels U, Stubenrauch KG, Benz J, Ehler A, Lauer ME, Ringler P, Kobold S, Endres S, Klein Ch, Brinkmann U.
Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies.
Biological Chemistry 2022; 403:495-508.
JIF 5.2

84. Roas M, Vick B, Kasper MA, Able M, Polzer H, Gerlach M, Kremmer E, Hecker JS, Schmitt S, Stengl A, Waller V, Hohmann N, Festini M, Ludwig AE, Rohrbacher L, Herold T, Subklewe M, Götze KS, Hackenberger CPR, Schumacher D, Helma-Smets J, Jeremias I, Leonhardt H, Spiekermann K.
Targeting FLT3 by new-generation antibody-drug-conjugate in combination with kinase inhibitors for treatment of AML.
Blood 2022; 2021015246. doi: 10.1182
JIF 25.5

83. Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, Scheurer M, Muth A, Hänel G, Nixdorf D, Sponheimer M, Ohlmeyer M, Lacher SM, Brauchle B, Marcinek A, Rohrbacher L, Leutbecher A, Rejeski K, Weigert O, von Bergwelt-Baildon M, Theurich S, Kischel R, Jeremias I, Bücklein VL, Subklewe M.
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
Blood 2022; 140:1104-1118.
JIF 25.5

82. Böttcher M, Böttcher-Loschinski R, Kahlfuss S, Aigner M, Gießl A, Mackensen A, Schlötzer-Schrehardt U, Tüting T, Bruns H, Mougiakakos D.
CLL-derived extracellular vesicles impair T-cell activation and foster T-cell exhaustion via multiple immunological checkpoints.
Cells 2022; 11:2176.
JIF 7.7

81. Böttcher M, Panagiotidis K, Bruns H, Stumpf M, Völkl S, Geyh S, Dietel B, Schroeder T, Mackensen A, Mougiakakos D.
Bone marrow stroma cells promote induction of a chemoresistant and prognostic unfavorable S100A8/A9high AML cell subset.
Blood Advances 2022;7:e2021005938.
JIF 7.6

80. Stazzoni S, Böhmer D, Hernichel F, Özdemir D, Pappa A, Drexler D, Bauernfried S, Witte G, Wagner M, Veth S, Hopfner KP, Hornung V, König LM, Carell T.
Novel poxin stable cGAMP-derivatives are remarkable STING agonists.
Angewandte Chemie 2022; 10:e202207175.
JIF 15.3

79. Bashiri Dezfouli A, Yazdi M, Benmebarek MR, Schwab M, Michaelides S, Miccichè A, Geerts D, Stefan S, Klapproth S, Wagner E, Kobold S, Gabriele Multhoff G.
CAR T cells targeting membrane-bound Hsp70 on tumor cells mimic Hsp70-primed NK cells.
Frontiers in Immunology 2022; 13:883694.
JIF 8.8

78. Stock S, Benmebarek MR, Kluever AK, Darowski D, Jost C, Stubenrauch KG, Benz J, Freimoser-Grundschober A, Moessner E, Umana P, Subklewe M, Endres S, Klein C, Kobold S.
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Journal for ImmunoTherapy of Cancer 2022;10:e005054.
JIF 12.5

77. Scheck MK, Lehmann L, Zaucha M, Schwarzlmueller P, Huber K, Pritsch M, Barba-Spaeth G, Thorn-Seshold O, Krug AB, Endres S, Rothenfusser S, Thorn-Seshold J.
FluoRNT: A robust, efficient assay for the detection of neutralising antibodies against yellow fever virus 17D.
PLOS One 2022; 17:e0262149.
JIF 3.8

76. Kolorz J, Demir S, Gottschlich A, Beirith I, Ilmer M, Lüthy D, Walz Ch, Dorotskar MM, Magg Th, Hauck F, von Schweinitz D, Kobold S, Kappler R, Berger M.
The neurokinin-1 receptor is a target in pediatric rhabdoid tumors.
Current Oncology 2022; 29:94-110.
JIF 3.1

75. Jetani H, Navarro-Bailón A, Maucher M, Frenz S, Verbruggen C, Yeguas A, Vidriales MB, González M, Rial Saborido J, Kraus S, Mestermann K, Thomas S, Bonig H, Luu M, Monjezi R, Mougiakakos D, Sauer M, Einsele H, Hudecek M.
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
Blood 2021; 138:1830-1842
JIF 22.1

74. Kurgyis Z, Vornholz L, Pechloff K, Kemény LV, Wartewig T, Muschaweckh A, Joshi A, Kranen K, Hartjes L, Möckel S, Steiger K, Hameister E, Volz T, Mellet M, French LE, Biedermann T, Korn T, Ruland J.
Keratinocyte-intrinsic BCL10/MALT1 activity initiates and amplifies psoriasiform skin inflammation.
Science Immunology 2021; 6:eabi4425
JIF 30.7

73. Darwich A, Silvestri A, Benmebarek MR, Mouries J, Melacarne A, Cadilha B, Taleb A, Supino D, Obeck H, Sustmann C, Morelli L, Masci G, Losurdo A, Curigliano G, Kobold S, Penna G, Rescigno M.
Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by Chitinase 3-like-1.
Journal for Immunotherapy of Cancer 2021; 9:e003224.
JIF 13.8

72. Tahk S, Vick B, Hiller B, Schmitt S, Marcinek A, Perini ED, Leutbecher A, Augsberger C, Reischer A, Tast B, Humpe A, Jeremias I, Subklewe M, Fenn NC, Hopfner KP.
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Journal of Hematology & Oncology 2021; 14:155.
JIF 10.7

71. Augsberger C, Hänel G, Xu W, Pulko V, Hanisch LJ, Augustin A, Challier J, Hunt K, Vick B, Rovatti PE, Krupka C, Rothe M, Schönle A, Sam J, Lezan E, Ducret A, Ortiz-Franyuti D, Walz AC, Benz J, Bujotzek A, Lichtenegger FS, Gassner C, Carpy A, Lyamichev V, Patel J, Konstandin NP, Tunger A, Schmitz M, von Bergwelt-Baildon M, Spiekermann K, Vago L, Jeremias I, Marrer-Berger E, Umaña P, Klein C, Subklewe M.
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC specific T-cell bispecific antibody.
Blood 2021; 138: 2655-69
JIF 22.1

70. Rejeski K, Perez Perez A, Sesques P, Hoster E, Berger CS, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Buecklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge WA, Ayuk F, Bachy E, Salles GA, Jain MD, Subklewe M.
CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.
Blood 2021; 138: 2499-513
JIF 22.1

69. Gaitzsch E, Passerini V, Khatamzas E, Strobl CD, Muenchhoff M, Scherer C, Osterman A, Heide M, Reischer A, Subklewe M, Leutbecher A, Tast B, Ruhle A, Weiglein T, Stecher SS, Stemmler HJ, Dreyling M, Girl P, Georgi E, Wölfel R, Mateyka L, D'Ippolito E, Schober K, Busch DH, Kager J, Spinner CD, Treiber M, Rasch S, Lahmer T, Iakoubov R, Schneider J, Protzer U, Winter C, Ruland J, Quante M, Keppler OT, von Bergwelt-Baildon M, Hellmuth J, Weigert O.
COVID-19 in patients receiving CD20-depleting immunochemotherapy for B-cell lymphoma.
Hemasphere 2021; 5:e603
JIF 1.6

68. Linder A, Bothe V, Linder N, Schwarzlmueller P, Dahlström F, Bartenhagen C, Dugas M, Pandey D, Thorn-Seshold J, Boehmer DFR, Koenig LM*, Kobold S, Schnurr M*, Raedler J, Spielmann G, Karimzadeh H, Schmidt A, Endres S, Rothenfusser S.
Defective interfering genomes and the full-length viral genome trigger RIG-I after infection with vesicular stomatitis virus in a replication dependent manner.
Frontiers Immunology 2021; 12:595390
JIF 7.6
*contributed equally

67. Boehmer DFR, Formisano S, de Oliveira Mann CC, Mueller SA, Kluge M, Metzger P, Rohlfs M, Hörth C, Kocheise L, Lichtenthaler SF, Hopfner KP, Endres S, Rothenfusser S, Friedel CC, Duewell P, Schnurr M, Koenig LM.
OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis.
Science Immunology 2021; 6:eabe2550
JIF 30.7

66. Prokopi A, Tripp CH, Tummers B, Hornsteiner F, Spoeck S, Crawford JC, Clements DR, Efremova M, Hutter K, Bellmann L, Cappellano G, Cadilha BL, Kobold S, Boon L, Ortner D, Trajanoski Z, Chen S, de Gruijl TD, Idoyaga J, Green DR, Stoitzner P.
Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
The Journal of Immunotherapy for Cancer 2021; 9:e000832
JIF 10.3

65. Karaki S, Blanc C, Tran T, Galy-Fauroux I, Mougel A, Dransart E, Anson M, Tanchot C, Paolini L, Gruel N, Gibault L, Lepimpec-Barhes F, Fabre E, Benhamouda N, Badoual C, Damotte D, Donnadieu E, Kobold S, Mami-Chouaib F, Golub R, Johannes L, Tartour E.
CXCR6 deficiency impairs cancer vaccine efficacy and CD8+ resident memory T-cell recruitment in head and neck and lung tumors.
The Journal of Immuntherapy for Cancer 2021; 9:e001948
JIF 13.0

64. Sams L, Kruger S, Heinemann V, Bararia D, Haebe S, Alig S, Haas M, Zhang D, Westphalen CB, Ormanns S, Metzger P, Werner J, Weigert O, von Bergwelt-Baildon M, Rataj F, Kobold S, Boeck S.
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plusnab-paclitaxel.
Clinical and Translational Oncology 2021; 23:2394-2401
JIF 2.8

63. Blaeschke F, Stenger D, Apfelbeck A, Cadilha BL, Benmebarek MR, Mahdawi J, Ortner E, Lepenies M, Habjan N, Rataj F, Willier S, Kaeuferle T, Majzner RG, Busch DH, Kobold S, Feuchtinger T.
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins.
Blood Cancer Journal 2021; 11:108
JIF 8.0

62. Di Pilato M*, Kfuri-Rubens R*, Pruessmann JN*, Ozga AJ*, Messemaker M, Cadilha BL, Sivakumar R, Cianciaruso C, Warner RD, Marangoni F, Carrizosa E, Lesch S, Billingsley J, Perez-Ramos D, Zavala F, Rheinbay E, Luster AD, Gerner MY, Kobold S, Pittet MJ, Mempel TR.
CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment.
Cell 2021; 184:4512-30
JIF 38.6
*contributed equally

61.Tokarew NJA, Suárez-Gosálvez J, Nottebrock A, Briukhovestka D, Endres S, Cadilha BL, Kobold S.
Flow cytometry detection and quantification of CAR T cells into solid tumors.
Methods in Cell Biology 2021; 167: 99-122
JIF 1.4

60. Schneider MA, Heeb L, Beffinger MM, Pantelyushin S, Linecker M, Roth L, Lehmann K, Ungethüm U, Kobold S, Graf R, van den Broek M, Vom Berg J, Gupta A, Clavien PA.
Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models.
Science Translational Medicine 2021; 13:eabc8188
JIF 21

59. Tahk S, Vick B, Hiller B, Schmitt S, Marcinek A, Perini ED, Leutbecher A, Augsberger C, Reischer A, Tast B, Humpe A, Jeremias I, Subklewe M, Fenn NC, Hopfner KP.
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Journal of Hematology Oncology 2021; 14:155
JIF 10.7

58. Ecker V, Stumpf M, Brandmeier L, Neumayer T, Pfeuffer L, Engleitner T, Ringshausen I, Nelson N, Jücker M, Wanninger S, Zenz T, Wendtner C, Manske K, Steiger K, Rad R, Müschen M, Ruland J, Buchner M.
Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia.
Nature Communications 2021; 12:3526
JIF 12.1

57. Cadilha BL, Benmebarek MR, Dorman K, Oner A, Lorenzini T, Obeck H, Vänttinen M, Di Pilato M, Pruessmann JN, Stoiber S, Huynh D, Märkl F, Seifert M, Manske K, Suarez-Gosalvez J, Zeng Y, Lesch S, Karches CH, Heise C, Gottschlich A, Thomas M, Marr C, Zhang J, Pandey D, Feuchtinger T, Subklewe M, Mempel TR, Endres S, Kobold S.
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors.
Science Advances 2021;7:eabi5781
JIF 14

56. Brand I, Gilberg L, Bruger J, Garí M, Wieser A, Eser TM, Frese J, Ahmed MIM, Rubio-Acero R, Guggenbuehl Noller JM, Castelletti N, Diekmannshemke J, Thiesbrummel S, Huynh D, Winter S, Kroidl I, Fuchs C, Hoelscher M*, Roider J*, Kobold S*, Pritsch M*, Geldmacher C*.
Broad T cell targeting of structural proteins after SARS-CoV-2 infection: High throughput assessment of T cell reactivity using an automated interferon gamma release assay.
Frontiers in Immunology 2021; 12:688436.
JIF 5.1 *contributed equally

55. Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha BL, Dantes Z, Rataj F, Dorman K, Lutz J, Karches CH, Heise C, Kurzay M, Larimer BM, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth C, Benmebarek MR, Dhoqina D, Grünmeier R, Seifert M, Oener A, Umut Ö, Joaquina S, Vimeux L, Tran T, Hank T, Baba T, Huynh D, Megens RTA, Janssen KP, Jastroch M, Lamp D, Ruehland S, Di Pilato M, Pruessmann JN, Thomas M, Marr C, Ormanns S, Reischer A, Hristov M, Tartour E, Donnadieu E, Rothenfusser S, Duewell P, König LM, Schnurr M, Subklewe M, Liss AS, Halama N, Reichert M, Mempel TR, Endres S, Kobold S.
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.
Nature Biomedical Engineering 2021; 5: 1246-60
JIF 26.0

54. Frey L, Ziętara N, Łyszkiewicz M, Marquardt B, Mizoguchi Y, Linder MI, Liu Y, Giesert F, Wurst W, Dahlhoff M, Schneider MR, Wolf E, Somech R, Klein C.
Mammalian VPS45 orchestrates trafficking through the endosomal system.
Blood 2021; 137:1932-1944.
JIF 17.5

53. Rohrbacher L, Brauchle B, Ogrinc Wagner A, von Bergwelt-Baildon M, Bücklein VL, Subklewe M.
The PI3K∂-selective inhibitor idelalisib induces T- and NK-cell dysfunction independently of B-cell malignancy-associated immunosuppression.
Frontiers in Immunology 2021; 12: 608625.
JIF 5.1

52. Alankus B, Ecker V, Vahl N, Braun M, Weichert W, Macher-Göppinger S, Gehring T, Neumayer T, Zenz T, Buchner M, Ruland J.
Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia.
Journal of Experimental Medicine 2021; 218: e20200517
JIF 11.7

51. Benmebarek MR, Cadilha BL, Herrmann M, Lesch S, Schmitt S, Stoiber S, Darwich A, Augsberger C, Brauchle B, Rohrbacher L, Oner A, Seifert M, Schwerdtfeger M, Gottschlich A, Rataj F, Fenn NC, Klein C, Subklewe M, Endres S, Hopfner KP, Kobold S.
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Leukemia 2021; 7:1–15.
JIF 9.9

50. Schmitt S, Tahk S, Lohner A, Hänel G, Maiser A, Hauke M, Patel L, Rothe M, Josenhans C, Leonhardt H, Griffioen M, Deiser K, Fenn NC, Hopfner KP and Subklewe M.
Fusion of bacterial flagellin to a dendritic cell-targeting αCD40 antibody construct coupled with viral or leukemia-specific antigens enhances dendritic cell maturation and activates peptide-responsive T cells.
Frontiers in Immunology,2020; 12: 602802. doi: 10.3389
JIF 5.1

49. Brix N, Samaga D, Hennel R, Gehr K, Zitzelsberger H, Lauber K.
The clonogenic assay: robustness of plating efficiency-based analysis is strongly compromised by cellular cooperation.
Radiation Oncology 2020; 15:248.
JIF 2.8

48. Ernst A, Hennel R, Krombach J, Kapfhammer H, Brix N, Zuchtriegel G, Uhl B, Reichel CA, Frey B, Gaipl US, Winssinger N, Shirasawa S, Sasazuki T, Sperandio M, Belka C, Lauber K.
Priming of Anti-tumor Immune Mechanisms by Radiotherapy Is Augmented by Inhibition of Heat Shock Protein 90.
Frontiers in Oncology 2020; 10:1668.
JIF 4.7

47. Willier S, Rothämel P, Hastreiter M, Wilhelm J, Stenger D, Blaeschke F, Rohlfs M, Kaeuferle T, Schmid I, Albert MH, Binder V, Subklewe M, Klein C, Feuchtinger T.
CLEC12A and CD33 co-expression as preferential target on pediatric AML for combinatorial immunotherapy.
Blood 2020; 137:1037-49. doi: 101182
JIF 10.7

46. Piseddu I, Röhrle N, Knott MML, Moder S, Eiber S, Schnell K, Vetter V, Meyer B, Layritz P, Kühnemuth B, Wiedemann GM, Gruen J, Perlberg C, Rapp M, Endres S, Anz D.
Constitutive expression of CCL22 is mediated by T cell-derived GM-CSF.

The Journal of Immunology 2020; 205:2056-2065.
JIF 4.3

45. Boehmer D, Koehler L, Magg T, Metzger P, Rohlfs M, Ahlfeld J, Rack-Hoch A, Reiter K, Albert M, Endres S, Rothenfusser S, Klein Ch, Koenig L, Hauck F.
A novel complete autosomal recessive STAT1 LOF variant causes immunodeficiency with hemophagocytic lymphohistiocytosis-like hyperinflammation.
The Journal of Allergy and Clinical Immunology 2020; 8:3102-3111
JIF 10.3

44. Geiger M, Stubenrauch KG, Sam J, Richter W, Jordan G, Eckmann J, Hage C, Gonzalez-Nicolini V, Freimoser-Grundschober A, Ritter M, Lauer M, Stahlberg H, Ringler P, Patel J, Sullivan E, Grau-Richards S, Endres S, Kobold S, Umaña P, Brünker P, Klein Ch.

Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
Nature Communications 2020; 24:3196
JIF 12.3

43. Metzger P, Kirchleitner S, Boehmer D, Hörth Ch, Eisele A, Ormanns S, Gunzer M, Lech M, Lauber K, Endres S, Duewell P, Schnurr M, König LM.
Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
Cancer Immunology Immunotherapy 2020; 69:2101-2112
JIF 4.9

42. Stenger D, Stief T, Kaeuferle T, Willier S, Rataj F, Schober K, Binje V, Lotfi R, Wagner B, Grünewald T, Kobold S, Busch D, Jeremias I, Blaeschka F, Feuchtinger T.
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Blood 2020; 17:1407-1418
JIF 10.7

41. Park E, Chen J, Moore A, Mangolini M, Santoro A, Boyd JR, Schjerven H, Ecker V, Buchner M, Williamson JC, Lehner PJ, Gasparoli L, Williams O, Bloehdorn J, Stilgenbauer S, Leitges M, Egle A, Schmidt-Supprian M, Frietze S, Ringshausen I.
Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance.
Science Translational Medicine 2020; 12:526
JIF 8.3

40. Tohumeken S, Baur R, Böttcher M, Stoll A, Loschinski R, Panagiotidis K, Braun M, Saul D, Völkl S, Baur AS, Bruns H, Mackensen A, Jitschin R, Mougiakakos D.
Palmitoylated proteins on AML-derived extracellular vesicles promote myeloid-derived suppressor cell differentiation via TLR2/Akt/mTOR signaling.
Cancer Research 2020; 80:3663-3676
JIF 9.7

39. Łyszkiewicz M, Ziętara N, Frey L, Pannicke U, Stern M, Liu Y, Fan Y, Puchałka J, Hollizeck S, Somekh I, Rohlfs M, Yilmaz T, Ünal E, Karakukcu M, Patiroğlu T, Kellerer C, Karasu E, Sykora KW, Lev A, Simon A, Somech R, Roesler J, Hoenig M, Keppler OT, Schwarz K, Klein C.
Human FCHO1 deficiency reveals role for clathrin-mediated endocytosis in development and function of T cells.
Nature Communications 2020; 11:1031.
JIF 12.3

38. Sustmann C, Dickopf S, Regula JT, Kettenberger H, Mølhøj M, Gassner C, Weininger D, Fenn S, Manigold T, Kling L, Künkele KP, Schwaiger M, Bossenmaier B, Griese JJ, Hopfner KP, Graff-Meyer A, Stahlberg H, Ringler P, Lauer ME, Brinkmann U, Schaefer W, Klein C.
DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.
MAbs. 2019;11:1402-1414.
JIF 4.4

37. Helms M, Jahn-Hofmann K, Gnerlich F, Metz-Weidmann,C, Braun M, Dietert G, Scherer P, Grandien K, Theilhaber J, Cao H, Wagenaar T, Schnurr M, Endres S, Wiederschain D, Scheidler S, Rothenfusser S, Brunner B, König LM.
Utility of the RIG-I agonist triphosphate RNA for melanoma therapy.
Molecular Cancer Therapeutics 2019; 18:2343-2356.
JIF 4.9

36. Mountford SA, Ringleb A, Schwaiger R, Mayr D, Kobold S, Dinarello Ch, Bufler P.
Interleukin-37 inhibits colon carcinogenesis during chronic colitis.
Frontiers in Immunology 2019; 10:2632.
JIF 4.7

35. Darowski D, Jost Ch, Stubenrauch K, Wessels U, Benz J, Ehler A, Freimoser-Grundschober A, Brünker P, Mössner E, Umana P, Kobold S, Klein Ch.
P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation.
Protein Engineering, Design and Selection 2019; 32:207-218
JIF 2.0

34. Lorenz G, Moschovaki-Filippidou F, Würf V, Metzger P, Steiger S, Batz F, Carbajo-Lozoya J, Koziel J, Schnurr M, Cohen C, Schmaderer C, Anders H, Lindenmeyer M, Lech M.
IFN regulatory factor 4 controls post-ischemic inflammation and prevents chronic kidney disease.
Frontiers in Immunology 2019; 10:2162
JIF 4.7

33. Metzger P, Kirchleitner S, Kluge M, Koenig L, Hoerth Ch, Rambuscheck CA, Boehmer D, Ahlfeld J, Kobold S, Friedel C, Endres S, Schnurr M, Duewell P.
Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer.
Journal for Immunotherapy of Cancer 2019; 7:288
JIF 8.7

32. Ruzicka M*, König L*, Formisano S, Boehmer D, Vick B, Heuer EM, Meinl H, Kocheise L, Zeitlhoefler M, Ahlfeld J, Kobold S, Endres S, Subklewe M, Duewell P, Schnurr M, Jeremias I, Lichtenegger F*, Rothenfusser S*.
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Leukemia 2019; 34:1017-1026
JIF 9.9
* contributed equally to this study

31. Wiedemann G, Röhrle N, Makeschin MC, Fesseler J, Endres S, Mayer D, Anz D.
Peritumoral CCL1 and CCL2 expressing cells in hepatocellular carcinomas shape the tumor immune infiltrate.
Pathology 2019; 51:586-592
JIF 3.2

30. Karches C*, Benmebarek MR*, Schmidbauer M, Kurzay M, Klaus R, Geiger M, Rataj F, Cadilha BL, Lesch S, Heise C, Murr R, vom Berg J, Jastroch M, Lamp D, Ding J, Duewell P, Niederfellner G, Sustmann C, Endres S, Klein Ch, Kobold S.
Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy.
Clinical Cancer Research 2019; 25:5890-5900
JIF 8.9
* contributed equally to this study

29. Rapp M, Wintergerst M, Kunz W, Vetter V, Knott M, Lisowski D, Haubner S, Moder S, Thaler R, Eiber S, Meyer B, Röhrle N, Piseddu I, Grassmann S, Layritz P, Kühnemuth B, Stutte S, Bourquin C, von Andrian U, Endres S, Anz D.
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.
Journal of Experimental Medicine 2019; 116:5514-5522.
JIF 10.9

28. Liu X, Li J, Cadilha BL, Markota A, Voigt C, Huang Z, Lin P, Wang D, Juncheng D, Kranz G, Krandick A, Libl D, Zitzelsberger H, Zagorski I, Braselmann H, Pan M, Zhu S, Huang Y, Niedermeyer S, Reichel Ch, Uhl B, Briukhovetska D, Suarez Gosalvez J, Kobold S, Gires O, Wang H.
Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis.
Science Advances 2019; 5:eaav4275.
JIF 11.5

27. Rataj F, Jacobi S, Stoiber S, Asang F, Ogonek J, Tokarew N, Cadilha BL, van Puijenbroek E, Heise C, Düwell P, Endres S, Klein Ch, Kobold S.
High affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
British Journal of Cancer 2019; 120:79-87
JIF 6.2

26. Wiedemann G, Aithal C, Kraechan A, Heise C, Cadilha BL, Zhang J, Duewell P, Ballotti R, Endres S, Bertolotto C, Kobold S.
Microphthalmia-associated transcription factor (MITF) regulates immune cell migration into melanoma.
Translational Oncology 2019; 12:350-360.
JIF 3.1

25. Jitschin R, Saul D, Braun M, Tohumeken S, Völkl S, Kischel R, Lutteropp M, Dos Santos C, Mackensen A, Mougiakakos D.
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
Journal for Immuno Therapy of Cancer 2018: 6:116

24. Keppler SJ, Burbage M, Gasparrini F, Hartjes L, Aggarwal S, Massaad MJ, Geha RS, Bruckbauer A, Batista FD.
The lack of WIP binding to actin results in impaired B cell migration and altered humoral immune responses.
Cell Reports 2018; 24:619-629

23. Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.
Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Blood 2018; 132:2484-2494

22. Rataj F, Kraus F, Chaloupka M, Grassmann S, Heise C, Cadilha BL, Duewell P, Endres S, Kobold S.
PD1-CD28 fusion protein enables CD4+ T cell help for adoptive T cell therapy in models of pancreatic cancer and non-Hodgkin-lymphoma.
Frontiers in Immunology 2018; 9:1955
JIF 6.4

21. Weidenbusch M, Song S, Iwakura T, Shi C, Rodler S, Kobold S, Mulay SR, Honarpisheh MM, Anders HJ.
IL-22 sustains epithelial integrity in progressive kidney remodeling and fibrosis.
Physiological Reports 2018; 6:e13817

20. Andrade L, Tay R, Pan D, Luoma A, Ito Y, Badrinath S, Tsoucas D, Franz B, May K, Harvey Ch, Kobold S, Pyrdol J, Yoon Ch, Yuan G, Hodi S, Dranoff G, Wucherpfennig K.
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity.
Science 2018; 359:1537-1542.

JIF 35.3

19. Damby D, Horwell C, Baxter P, Kueppers U, Schnurr M, Dingwell D, Duewell P.
Volcanic ash activates the NLRP3 inflammasome in murine and human macrophages.
Frontiers in Immunology 2018; 8:2000
JIF 6.4

18. Metzger P, Kirchleitner S, König L, Hörth Ch, Kobold S, Endres S, Schnurr M, Duewell P.
Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.
Science Reports 2018; 8
JIF 4.8

17. Makanyengo R, Duewell P, Reichl C, Hörth Ch, Lehr HA, Fischer S, Clavel T, Denk G, Hohenester S, Kobold S, Endres S, Schnurr M, Bauer Ch.

Nlrp3-dependent IL-1ß inhibits CD103+ dendritic cell differentiation in the gut.
Journal of Clinical Investigation 2018;
JIF 6,0

16. Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, Schlüter M, Neitz J, Subklewe M.
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.
Frontiers in Immunology 2018; 9:385.
JIF 5.5

15. Loschinski R, Böttcher M, Stoll A, Bruns H, Mackensen A, Mougiakakos D.
IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner.
Oncotarget 2018; 9(17): 13125-13138

14. Voigt C*, May P*, Gottschlich A*, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT, Arendt KAM, Heise C, Rataj F, Janssen KP, Königshofff M, Winter H, Himsl I, Thasler WE, Schnurr M, Rothenfußer S, Endres S and Kobold S.
Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth.
Proceedings of the National Academy of Sciences USA 2017; 114(49):12994-12999

JIF 9.6

* contributed equally to this study

13. Wennhold K, Thelen M, Schlößer HA, Haustein N, Reuter S, Garcia-Marquez M, Lechner A, Kobold S, Rataj F, Utermöhlen O, Chakupurakal G, Theurich S, Hallek M, Abken H, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M.
Using antigen-specific B cells to combine antibody and T cell-based cancer immunotherapy.
Cancer Immunology Research 2017; 5(9):730-743
JIF 8.2

12. Cadilha BL, Dormann K, Rataj F, Endres S and Kobold S.
Enabling T cell recruitment to tumours as a strategy for improving adoptive T cell therapy.
European Oncology and Hematology 2017; 13:66-73

11. Ponce LP, Fenn NC, Moritz N, Krupka C, Kozik JH, Lauber K, Subklewe M, Hopfner KP.
SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Oncotarget 2017; 8(7):11284-11301
JIF 5.0

10. Groß CJ, Mishra R, Schneider KS, Médard G, Wettmarshausen J, Dittlein DC, Shi H, Gorka O, König PA, Fromm S, Magnani G, Ćiković T, Hartjes L, Smollich J, Robertson AAB, Cooper MA, Schmidt-Supprian M, Schuster M, Schroder K, Broz P, Traidl-Hoffmann C, Beutler B, Kuster B, Ruland J, Schneider S, Perocchi F, Groß O.

K+ efflux-independent NLRP3 inflammasome activation by a small molecule targeting mitochondria.
Immunity 2016; 45:1-13.
JIF 24.1

9. Qorraj M, Bruns H, Böttcher M, Weigand L, Saul D, Mackensen A, Jitschin R, Mougiakakos D.
The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.
Leukemia 2016; doi:10.1038/leu.2016.214.
JIF 12.1

8. Rapp M, Grassmann S, Chaloupka M, Layritz P, Kruger S, Ormanns S, Rataj F, Janssen KP, Endres S, Anz D, Kobold S.
C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer.
Oncoimmunology 2016; 5:e1105428.
JIF 7.3

7. Roskopf C, Braciak TA, Fenn NC, Kobold S, Fey GH, Hopfner KP, Oduncu FS.

Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.
Oncotarget 2016; 7:22579-22589.
JIF 5.0

6. Wiedemann G, Jacobi S, Chaloupka M, Hamm S, Strobl S, Baumgartner R, Rothenfusser S, Duewell P, Endres S, Kobold S.
A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.
Oncoimmunology 2016; 5:e1189051.
JIF 7.3

5. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf C, Wildenhain S, Honegger A, Schubert IA, Schele A, Lämmermann K, Fey GH, Jacob U, Lang P, Hopfner KP, Oduncu FS.
CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B lymphoid cells.
Oncotarget; 7:83392-83408.
JIF 5.0

4. Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger JC, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner G, Klein C, Bourquin C, Endres S.
Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.
The Journal of the National Cancer Institute 2015; 107:364.
JIF 15.2

3. Kobold S*, Grassmann S*, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Duewell P, Zeng Y, Schmollinger J, Schnurr M, Endres S#, Rothenfußer S#.
Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy.
The Journal of the National Cancer Institute 2015; 107: djv146.
JIF 15.2
* contributed equally to this study, # share senior authorship

2. Ernst A, Anders H, Kapfhammer H, Orth M, Hennel R, Seidl K, Winssinger N, Belka C, Unkel S, Lauber K.
HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas.
Cancer Letters 2015; 365:211-222.
JIF 5.0

1. Duewell P, Beller E, Kirchleitner S, Adunka T, Bourhis H, Siveke J, Mayr D, Kobold S, Endres S, Schnurr M.
Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.
Oncoimmunology 2015; 4: e1029698.
JIF 6.3

22. Rial Saborido J, Völkl S, Aigner M, Mackensen A, Mougiakakos D.
Role of CAR T Cell Metabolism for Therapeutic Efficacy.
Cancers (Basel) 2022;14:5442.

21. Huynh D, Winter P, Märkl F, Endres S, Kobold S.
Beyond direct killing-novel cellular immunotherapeutic strategies to reshape the tumor microenvironment.
Seminars in Immunopathology 2023;45:215-227.

20. Märkl F, Huynh D, Endres S, Kobold S.

Utilizing chemokines in cancer immunotherapy.
Trends in Cancer 2022;8:670-82.
JIF

19. Stock S, Kluever AK, Endres S, Kobold S.
Enhanced Chimeric antigen receptor T cell therapy through co-application of synergistic combination Partners.
Biomedicines 2022;28;10:307.
JIF

18. Umut Ö, Gottschlich A, Endres S, Kobold S.

CAR T cell therapy in solid tumors: a short review.
Magazine of European Medical Oncology 2021;14:143-49.
JIF

17. Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S.
Interleukins in cancer: from biology to therapy.
Nature Reviews Cancer 2021; 21:481-99.
JIF

16. Schwerdtfeger M, Benmebarek MR, Endres S, Subklewe M, Desiderio V, Kobold S.
Chimeric antigen receptor-modified T cells and T cell-engaging bispecific antibodies: Different tools for the same Job.
Current Hematologic Malignancy Report 2021;16: 218-233.
JIF 2.5

15. Vornholz L, Ruland J.
Physiological and Pathological Functions of CARD9 Signaling in the Innate Immune System.
Current Topics Microbiology and Immunology 2020; 429: 177-203 

14. Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M.
Advances in cancer immunotherapy 2019 - latest trends.
Journal of Expimental and Clinical Cancer Research 2019; 38:268.

13. Lesch S, Benmebarek MR, Cadilha BL, Stoiber S, Subklewe M, Endres S, Kobold S.
Determinants of response and resistance to CAR T cell therapy.
Seminars in Cancer Biology 2019, 6: S1044-579

12. Stoiber S, Cadilha BL, Benmebarek MR, Lesch S, Endres S, Kobold S.
Limitations in the design of chimeric antigen receptors for cancer therapy.
Cells 2019; 8:E472:1-26

11. Benmebarek MR, Karches C, Cadilha BL, Lesch S, Endres S, Kobold S.
Killing mechanisms of chimeric antigen receptor (CAR) T cells.
International Journal of Molecular Sciences 2019; 20(6)

10. Hartjes L, Ruland J.
CARD9 Signaling in Intestinal Immune Homeostasis and Oncogenesis.
Frontiers in Immunology 2019; 11

9. Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K.
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
Radiation Oncology 2019 14:1 - 20

8. Ruland J, Hartjes L.
CARD-BCL-10-MALT1 signalling in protective and pathological immunity.
Nature Reviews Immunology 2019; 2:118-134

7. Cadilha BL, Dorman K, Rataj F, Endres S, Kobold S.
Enabling T cell recruitment to tumors as a strategy for improving adoptive T cell therapy.
European Oncology and Haematology 2017; 13:66-73.

6. Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K.
Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences.
Immunological Reviews 2017; 280:249-279

5. Bauer C, Kühnemuth B, Düwell P, Ormanns S, Gress T, Schnurr M.
Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.

Cancer Letters 2016; 381:259-268.

4. Lauber K, Brix N, Ernst A, Hennel R, Krombach J, Anders H, Belka C.

Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity.

Cancer Letters 2015; 15:162-167.
JIF 5.0

3. Schnurr M, Düwell P, Bauer C, Rothenfusser S, Lauber K, Endres S, Kobold S.

Strategies to relieve immunosuppression in pancreatic cancer.
Immunotherapy 2015; 7:363-376.

JIF 2.4

2. Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.
Immunotherapy of tumors – Activated T cells as a new treatment modality.

Deutsches Ärzteblatt International 2015; 112:809-15.

JIF 3.7

1. Kobold S, Wiedemann G, Rothenfusser S, Endres S.

Modes of action of TLR7 agonists in cancer therapy.

Immunotherapy 2014; 6:1085-95.

JIF 2.4